Available in Spain, Brazil, United States
The primary objectives of the study are to demonstrate superiority of neoadjuvant
Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy
relative to neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant
pembrolizumab with or without chemotherapy in participants with previously untreated TNBC
or hormone receptor-low/HER2-negative breast cancer, by investigator assessment of EFS.
1900Patients around the world